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A better understanding of the molecular mechanisms required for schistosomes to
take up glucose, the major nutritional source exploited by these blood flukes from
their mammalian hosts and the subsequent metabolism required to fuel growth and
fecundity, can provide new avenues for developing novel interventions for the control
of schistosomiasis. This aspect of parasitism is particularly important to paired adult
schistosomes, due to their considerable requirements for the energy needed to produce
the extensive numbers of eggs laid daily by the female worm. This review describes
recent advances in characterizing glucose metabolism in adult schistosomes. Potential
intervention targets are discussed within the insulin signaling and glycolysis pathways,
both of which play critical roles in the carbohydrate and energy requirements of
schistosomes.
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INTRODUCTION
Schistosomiasis remains one of the most devastating tropical
parasitic diseases (Colley et al., 2014), with an estimated 200
million people infected (85% live in Africa), and about 700
million people at risk in 74 countries (Nour, 2010). This is
despite the availability of a highly effective drug [praziquan-
tel (PZQ)] and extensive ongoing control programs involving
mainly mass drug administration. Important shortcomings of
PZQ include its relative inactivity against migratory juveniles
and developing worms (Gonnert and Andrews, 1977) and its
inability to prevent reinfection. Schistosomes have a complex
life cycle, with discrete stages perfectly adapted to their differ-
ing host and free-living environments, to promote survival and
transmission. The mammalian endoparasitic life cycle begins
with the penetration of cercariae, released from freshwater snails,
though host skin; then these larvae develop into schistosomula
which move to the lungs and pass down the mesenteric vas-
culature (S. mansoni, S. japonicum) or urinary bladder venous
plexus (S. haematobium) where host signals stimulate further
development of the juvenile males and females. Pairing and
sexual maturation of the adult worms results in extensive egg
production. It is the schistosome eggs that are responsible for
both the severe pathology associated with schistosomiasis, due
to granuloma formation around the ova trapped in tissues,
and transmission. The latter is dependent upon the eggs being
released from the definitive mammalian host into water and
their hatching to release miracidia which penetrate the appro-
priate freshwater snail intermediate host. Within the haemocoel
of the snail, the miracidia form sporocysts, in which further
asexual propagation releases larval cercariae. Such processes of
multiplication and proliferation are highly energy consuming and
schistosomes are entirely reliant on their hosts for the essen-
tial nutrients they require for development, reproduction and
metabolism.
It is anticipated that better strategies, including vaccines, for
schistosomiasis control will rely on an improved understanding
of how schistosomes utilize host nutrients, neuro-endocrine
hormones and signaling for their survival, development and
maturation. Comprehensive deciphering of the available schis-
tosome genomes, transcriptomes, and proteomes is becoming
increasingly important for understanding the highly adapted
relationship between parasite and hosts on the path to iden-
tifying novel drug or vaccine targets (Berriman et al., 2009;
Schistosoma japonicum Genome Sequencing and Functional
Analysis Consortium, 2009; Young et al., 2012). Resident in
the mammalian host bloodstream, schistosomes import essen-
tial nutrients across the body surface and through the gut and
it is striking that the adult worms consume their dry weight
of glucose from the host every 5 h (Bueding, 1950) in order
to survive. Here, we focus on the molecular features associ-
ated with glucose uptake and metabolism in schistosomes during
the intra-mammalian stages of development. We also discuss
the essential role these processes play in worm development,
growth and maturation, and the potential for the associated
molecular components might have as novel vaccine or drug
targets.
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CLONING AND CHARACTERIZATION OF SCHISTOSOME
GLUCOSE TRANSPORTER PROTEINS
It is recognized that glucose is the common currency of cellular
metabolism and all cells import glucose across their hydropho-
bic surface membranes using glucose transporter proteins (GTPs)
(Lienhard et al., 1992). Four glucose transporters (SGTP1, 2, 3,
and 4) have been identified in S. mansoni (Skelly et al., 1994;
Krautz-Peterson et al., 2010), of which SGTP1 and SGTP4 dis-
play glucose transport activity, and are markedly inhibited by
cytochalasin B in Xenopus uptake assays (Skelly et al., 1994).
SGTP1 is present in a number of life stages (eggs, sporocysts, cer-
cariae, schistosomula and adult female and male worms) while
SGTP4 has been detected only in the intra-mammalian forms,
where it appears after the transformation of the cercariae into
schistosomula and the appearance of the double membrane of
the adult worm tegument (Skelly and Shoemaker, 1996). Both
SGTP1 and SGTP4 are localized to the tegument of adult worms
and schistosomula (Skelly and Shoemaker, 1996). SGTP4 seems
to be localized uniquely to the apical membranes of the tegu-
ment, while SGTP1 is located on the tegumental basal membrane
and within the worm body, particularly in muscle. This localiza-
tion of the two SGTPs in the schistosome tegument implies that
the host-interactive SGTP4 protein facilitates the import of glu-
cose from the host bloodstream into the tegument while SGTP1
serves to move free glucose from the surface into the intersti-
tial fluids providing a nutrient source for the internal tissues
(Zhong et al., 1995). Probing of cryosections of adult S. japon-
icum with anti-SGTP1 and SGTP4 antibodies showed the same
localization for SGTP1 and SGTP4 in the tegument of S. japon-
icum and S. mansoni suggesting sequence homology between the
SGTPs of the two species (Jiang et al., 1999). Sequencing of the
S. japonicum genome has indicated this is the case for SjGTP1
although only partial sequence is available for SjGTP4 (http://
chgc.sh.cn/japonicum/) (Supplementary Table 1). Full length
sequences for GTP1 and GTP4 have also been identified in S.
haematobium (Young et al., 2012) (Supplementary Table 1). RNAi
studies have shown that SGTP1- or SGTP4-suppressed schisto-
somula and adult worms of S. mansoni have an impaired ability
to transfer glucose (Krautz-Peterson et al., 2010). Worms having
both SGTP1 and SGTP4 suppressed showed a further decreased
capacity to take up glucose compared with worms having only
a single SGTP gene knocked down. Significantly fewer parasites
having SGTP-knocked down survived after prolonged culture
in glucose-depleted medium compared with controls. Further,
SGTP-knockdown parasites exhibited less viability in vivo after
infection of mice. Taken as a whole, these studies empha-
sized the important roles of SGTP1 and SGTP4 in the transfer
into schistosomes of exogenous glucose, which is the major
energy source for parasite survival and development in the
mammalian host.
In addition, SGTP2 and SGTP3 are also suspected to be
associated with glucose uptake in schistosomes. SGTP2 expres-
sion was shown to be limited to the female reproductive tract
(Skelly et al., 1998) but the protein did not appear to be func-
tional in glucose transport and it was speculated that a deletion
mutation in SGTP2 occurred in its recent evolutionary history
resulting in its loss of function (Skelly et al., 1994). In silico
annotation has indicated that SGTP3 (Smp_127200) is the most
recently identified component considered as a potential glu-
cose transporter in S. mansoni (Krautz-Peterson et al., 2010)
but further functional investigation is required to confirm this
observation.
SIGNAL TRANSDUCTION REGULATES SCHISTOSOME
GLUCOSE IMPORT
When considering GTPs in mammalian cells, it is impossible
to ignore the important role of insulin in the dual regula-
tion of increasing glucose uptake and glycogen synthesis (glyco-
genesis). The Caenorhabditis elegans genome encodes a single
insulin/IGF-1-like receptor (daf-2) and 40 members of insulin-
like peptides (ILPs) (Li et al., 2003). Recently, it has been con-
firmed that in C. elegans, daf-2 modulates glucose transport via
the insulin signaling pathway, in similar manner to that found
in mammalian cells (Beall and Pearce, 2002). Whether insulin
regulates glucose uptake in schistosomes by a similar mecha-
nism to that observed in C. elegans remains to be determined.
Schistosomes are unable to synthesize insulin (2009) although
insulin-degrading proteases (inferred from annotation) have
been identified in S. japonicum (Sjp_0009920, http://chgc.sh.cn/
japonicum/) and S. mansoni (Smp_128100, http://www.genedb.
org/Homepage/Smansoni) which may have the same ability to
degrade the B chain of host insulin as mammalian cells (Affholter
et al., 1988). Microarray analysis demonstrated that adult worms
of S. japonicum depend on host insulin for growth and fecun-
dity (You et al., 2009). Insulin stimulates glucose uptake, improves
the viability of schistosome larvae in vitro (Vicogne et al., 2004)
and promotes the metabolism and development of adult worms
(Saule et al., 2005). These findings contrast with earlier reports
which suggested that insulin does not affect glucose consump-
tion by schistosomesin vitro (Clemens and Basch, 1989), and that
most glucose is imported by adult worms via carrier-mediated
diffusion (Skelly et al., 1998). The more recent study by Ahier
et al. (2008) has stressed the importance of insulin in modu-
lating glucose uptake in S. mansoni. Accordingly, two types of
insulin receptors, belonging to the large class of receptor tyro-
sine kinases (RTKs), have been isolated from S. mansoni (SmIR1
and 2) (Khayath et al., 2007) and S. japonicum (SjIR1 and 2)
(You et al., 2010), both of which are able to bind human insulin.
Transcription levels of the SjIRs were shown to be up-regulated
in mammalian stage parasites (adult worms and schistosomula),
further underpinning their involvement in the host-schistosome
interaction (You et al., 2010). The SjIRs are also highly expressed
in vitelline gland tissue suggesting an important role in supply-
ing nutrients and shell precursors for egg production, the major
function of the vitellaria (You et al., 2010). Whereas immunolo-
calization analysis showed that SmIR1 and SjIR1 are located at the
basal membrane of the tegument and in muscles of adult worms
(Khayath et al., 2007; You et al., 2010), and have the same location
as SGTP1 and SGTP4 (Skelly et al., 1994).While SmIR2 and SjIR2
are, instead, expressed in parenchymal cells of adult males and
vitelline cells of females, indicating the two receptor types could
have different functions (Khayath et al., 2007). On scrutiny of
the recently published S. haematobium genomic sequence (Young
et al., 2012) by protein BLAST, we identified only IR2, although
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it is likely that IR1 is also present. Further information on insulin
receptors in the three main clinically relevant schistosome species
is presented in Supplementary Table 1.
Notably, in a murine vaccine/challenge model of S.japonicum,
immunization with the L1 subdomain (which may contain the
insulin binding sites) of the SjIR fusion proteins expressed in
E. coli, resulted in highly significant reductions in fecal eggs
(56–67%), stunting of adult worms (12–42%), a reduction in
hepatic granuloma density (55%) and a reduction in the numbers
of mature intestinal eggs (75%) (You et al., 2012). The depression
in the development of mature eggs following SjIR vaccination
supports earlier observations that a low level of insulin in host
blood might hamper egg passage through the intestinal tissue
(Hulstijn et al., 2001).
The development of a safe, stable and effective vaccine based
on the ligand domains of SjIR1 and 2 using peptides derived
from their primary sequences, which are highly antigenic with
the ability to bind human insulin, may be feasible due to their
low homology to human IR (HIR). Additionally, the HIR con-
tains two receptor binding sites, which are the L1 domain and
the first and second type fibronectin III repeats of the insulin
receptor (Whittaker et al., 2008). The identification and charac-
terization of the fibronectin domains in the SjIRs, which have
considerably lower homology to HIR—but may be important in
changing the conformation of the kinase domain and through
inducing signaling transduction after binding with insulin—may
act as additional targets for blocking or interrupting the binding
between the SjIRs and host insulin.
Insulin signaling is an important metabolic pathway in reg-
ulating glucose uptake and glycogen synthesis in mammals.
Interrogation of the KEGG pathways assigned to metabolic pro-
cesses indicates a complete insulin signaling pathway is present
in S. japonicum (www.chgc.sh.cn/japonicum/sjpathway), com-
prising 43 genes with high homology with other species. Based
on published genome data, the 43 genes involved in the insulin
pathway have also been identified in S. mansoni (Berriman et al.,
2009) and S. haematobium (Young et al., 2012) (Supplementary
Table 2), further supporting the existence of a complete insulin
signaling pathway in schistosomes. The available information
strongly supports a similar role for schistosome IRs in down-
stream signal transduction for regulating glucose uptake as
occurs in mammalian cells (Figure 1). Both S. japonicum and
S. mansoni IRs have conserved α2β2 structures and struc-
ture modeling analysis showed the conserved structure between
the SjIRs and HIR, indicating a common predicted binding
interaction which occurs in the ligand domain, inducing the
same downstream signal transduction in the tyrosine kinase
domain (You et al., 2010). Several approaches including two-
hybrid analysis, microarray analysis and inhibitor studies in vitro
(Figure 1) have been used to further support the hypothesis
that glucose uptake in adult schistosome worms depends on
phosphorylation processes that could be modulated by insulin
pathways.
Tyrphostin AG1024 is a potent inhibitor of the RTK venus
kinase receptors of S. mansoni (Ahier et al., 2008; Vanderstraete
et al., 2013b). The venus kinase receptors, named because
they contain an atypical venus flytrap (VFT) motif in their
extracellular domain, usually present in G-protein coupled C
class receptors; the catalytic domains of SmIR1 and SmIR2 and
venus kinase receptors (SmVKR1 and SmVKR2) are similar
(Vanderstraete et al., 2013b). Both receptor types are important
for key biological processes in S. mansoni including metabolism
and reproduction (Vanderstraete et al., 2013a) and the IRs may
be essential in regulating glucose uptake (You et al., 2010).
Tyrphostin AG1024 was shown to simultaneously cause inhibi-
tion of the functional activity of SmIRs and SmVKRs leading
to the killing of both immature and adult S. mansoni in vitro.
This drug may prove useful for the future design of anti-kinase
compounds for anti-schistosome chemotherapy, and as an alter-
native drug to PZQ, which has no effect on immature worms
(Vanderstraete et al., 2013b). SmVKR1 and SmVKR2 are directly
associated with parasite growth and fecundity in schistosomes;
found only in invertebrates, they are activated by amino-acids
(Vicogne et al., 2003) and have an intracellular kinase domain
similar to that of SmIRs. These receptors are highly expressed in
larval S. mansoni and in ovaries of females, indicating involve-
ment in development and reproduction (Gouignard et al., 2012).
It is noteworthy that RTKs are considered as attractive anticancer
drug or vaccine targets (Arora and Scholar, 2005; Kuwai et al.,
2008).
Based on their important involvement in regulating the pro-
liferation and differentiation of vitelline cells and egg embryo-
genesis (Loverde et al., 2009), parasite RTKs, including IRs and
VKRs, transforming growth factor (TGF-β) receptors, epider-
mal growth factor (EGF) receptor and tumor necrosis factor-α
(TNF-α) receptor, have considerable potential as novel inter-
vention candidates against schistosomes and other helminths
parasites of clinical and veterinary importance (You et al.,
2011).
SCHISTOSOME GENES AND GENE PRODUCTS INVOLVED IN
GLYCOLYSIS AND GLYCOGENESIS
During their complex life cycle, schistosomes alternate between
consuming host glucose and stored glycogen to provide their
energy requirements. When a cercaria penetrates the definitive
host and transforms into a schistosomulum, the parasite switches
rapidly from carbon dioxide production via the Krebs cycle to
lactate production using glycolysis; lactate remains the main end
product of glucose degradation as schistosomes develop in their
mammalian hosts (Tielens, 1994). In tandem, schistosomes shift
rapidly from the consumption of stored glycogen to a dependence
on host glucose during the transformation phase from free-living
cercariae to schistosomula (Skelly et al., 1993). In the mam-
malian stages, schistosomula have low expression of respiratory
enzymes but regain their capacity for aerobic glucose metabolism
as they develop to adult worms (Skelly and Shoemaker, 1995).
Schistosomes express a range of mRNAs at relatively high lev-
els associated with anaerobic and oxidative glucose metabolism
during the transformation from cercaria to adult, re-emphasizing
the fact that adult worms possess a significant capacity to gen-
erate energy through aerobic metabolism (Skelly et al., 1993).
Glycogen synthesis has been shown to be indirectly propor-
tional to the amount of glycogen already present in adult worms,
which in turn is proportional to the size of the parasite (Tielens
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FIGURE 1 | Predicted insulin signaling pathway in schistosomes
based on the characterization of schistosome insulin receptors, the
published S. japonicum KEGG insulin pathway (www.chgc.sh.cn/
japonicum/sjpathway) and the human insulin pathway (http://
www.google . com/ imgres? imgurl=& imgrefurl=http%3A%
2F%2Fwww.abcam.com%2Findex .html%3Fpageconfig%
3Dresource%26rid%3D10602&h=0&w=0&tbnid=6ZKuhlAsT2VZXM&
zoom=1&tbnh=184&tbnw=274&docid=ETqKf7RmabxHnM&
tbm=isch&ei= IU2JU6fSDKmysQSx34BQ&ved=0CAIQs
CUoAA).
et al., 1990). It appears that glycogen is degraded intermittently
for specific purposes such as muscle contraction or tegumen-
tal membrane repair, with both functions being more prevalent
in adult males (Gobert et al., 2003). Interrogation of the KEGG
pathways assigned to metabolic processes indicates a complete
glycolytic pathway is present in S. japonicum (www.chgc.sh.cn/
japonicum/sjpathway), comprising 23 genes with high homol-
ogy with other species (Supplementary Figure 1; Supplementary
Table 3). Mining the published genomic data for S. mansoni
(Berriman et al., 2009) and S. haematobium (Young et al., 2012)
shows all 23 genes involved in glycolysis also occur in these two
species (Supplementary Table 3).
A number of the key enzymes involved in the glycolytic
pathway in schistosomes have been characterized; these include
enolase (Ramajo-Hernandez et al., 2007; De La Torre-Escudero
et al., 2010), triose-phosphate isomerize (TPI) (Yu et al., 2006;
Da’dara et al., 2008), glyceraldehyde 3-phosphate dehydrogenase
(G3PDH) (Goudot-Crozel et al., 1989; Charrier-Ferrara et al.,
1992), phosphofructokinase (PFK) (Mansour et al., 2000), phos-
phoglycerate kinase (PGK) (Lee et al., 1995), hexokinase and
glucose-6-phosphatise (Kuser et al., 2000). TPI, which converts
glyceraldehyde-3-phosphate to dehydroxyacetone phosphate, is a
lead anti-schistosome vaccine candidate (McManus and Loukas,
2008), generating an immune response that presumably reduces
the capacity of the blood fluke to metabolize glucose via glycolysis
for energy production. TPI is present in most cells of schisto-
some worms and has also been localized on the surface mem-
branes of the newly transformed schistosomulum (Harn et al.,
1992), the stage in the mammalian host that is the likely tar-
get of an anti-schistosome vaccine. TPI can induce protection
against S. japonicum challenge in mice (27.9% worm burden
reduction) (Zhu et al., 2002), pigs (48% worm reduction) (Zhu
et al., 2006) and water buffaloes (48–52% worm reduction) (Yu
et al., 2006; Da’dara et al., 2008). Enolase is another key gly-
colytic/gluconeogenic enzyme that is a physiological receptor of
plasminogen, a molecule which is essential for the activation of
the host fibrinolytic system, probably to prevent blood clot for-
mation on the schistosome worm surface (Ramajo-Hernandez
et al., 2007; De La Torre-Escudero et al., 2010). Disappointingly,
the protective efficacy of recombinant, functional enolase in
murine vaccine/S. japonicum challenge experiments is marginal
(Waine et al., 1993).
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OTHER COMPONENTS INVOLVED IN GLUCOSE UPTAKE
Acetylcholinesterase (AChE) has been indicated in the modu-
lation of glucose scavenging from mammalian host blood by
schistosomes (Camacho and Agnew, 1995). The glucose uptake
is regulated by acetylcholine (ACh) interaction with tegumen-
tal acetylcholine receptor (nAChR) and AChE. As reviewed by
Lee (1996), the secreted AChE may change host cell permeability,
have an anti-coagulant role, influence glycogenesis, and play an
important function in acetate and cholinemetabolism as has been
shown in nematodes. External AChE may cause the breakdown
of local host glycogen stores or block the conversion of glucose to
glycogen—as ACh stimulates glycogen synthesis—either of which
could make glucose more available in the local environment (Lee,
1996). The function of AChE is supposed to limit the interaction
of ACh with its receptor, because inhibition of AChE leads to an
effect that mimics ligand excess (Jones et al., 2002). These influ-
ences of ACh on glucose uptake can be inhibited through inhi-
bition in turn of either tegumental AChE or tegumental nAChR
(Jones et al., 2002). The mammalian stages of schistosomes have
AChE and nAChR on their teguments and both components are
concentrated on the surface of the adult male, a major surface site
for nutrient uptake for the worm pair. The rate of glucose import
in vitro by S. haematobium and S. bovis adult worm pairs was
shown to be enhanced by approximately 60% at blood (physio-
logical) concentrations of Ach, although S. mansoni did not show
a similar response (Camacho and Agnew, 1995). It is noteworthy
that AChE inhibition in adult worms results in the depletion of
tegumental but not muscle glycogen stores; this is relevant since
skeletal muscle acts as the primary site for insulin-stimulated
glucose disposal in mammals (Thabet et al., 2008). As this obser-
vation could not be attributed to the inhibition of glycogen
metabolism directly, disruption of sugar transport may have been
the cause (Camacho and Agnew, 1995). In vitro studies showed
that purified polyclonal antibodies against S. mansoni AChE were
cytotoxic, causing almost total complement-dependent killing of
the parasite (Espinoza et al., 1991; Arnon et al., 1999), suggest-
ing AChE may be a highly suitable candidate as a vaccine target,
especially as it is highly conserved across a variety of schisto-
some species (Espinoza et al., 1991) and anti-S. mansoni AChE
antibodies do not cross-react with human AChE (Espinoza et al.,
1991).
As discussed by Hu et al. (2003), cytokines and hormones
modulate the integrated response of mammalian hosts to infec-
tion by schistosomes. In addition to its essential involvement in
the host immune system, an unexpected role for Interleukin-
7 (IL-7) has been found in the development, maturation and
survival of schistosome worms in mammalian hosts. Infection
of mice deficient in IL-7 expression leads to parasite dwarfism
(Saule et al., 2002). In this model, IL-7 shares similar, but not
identical, effects with the thyroid hormone thyroxin (T4) (Saule
et al., 2003). This posed the question as to whether there is a com-
mon mediator to their action, which was hypothesized to be host
glucosemetabolism. Infection with S. mansoni resulted in an early
peak in glycaemia immediately followed by a peak of insulinemia.
In IL-7 + T4 co-treated infected animals, the peak of insulin was
abrogated (Saule et al., 2005). The same study further assessed the
consequences of experimentally induced glucose- or insulin-level
variations on parasite development. Insulin treatment led to
increased worm burden and parasite size, thus mimicking the
effect of T4 on schistosome development (Saule et al., 2005).
Finally, these treatments were also associated with an alteration
in the gene expression of schistosome components involved in
glucose import (Saule et al., 2005). Overall, IL-7 and T4 regu-
late schistosome glucose metabolism through modulations in the
circulating levels of host glucose and insulin (Saule et al., 2005).
OTHER DRUGS TARGETING GLUCOSE METABOLISM IN
SCHISTOSOMES
Artemether is a highly effective anti-malarial drug that also has
anti-schistosomal properties. The precise molecular target of the
drug in schistosomes remains unproven although there is some
evidence that artemether binds to SmSERCA, a putative Ca2+-
ATPase of Schistosoma (Lepore et al., 2011). Artemether has
also been shown to display apparent effects on the carbohydrate
metabolism of schistosomes (Zhai et al., 2000b) and key gly-
colytic enzymes, such as PFK (Xiao et al., 1998) and enolase
(Zhai et al., 2000a), any of which might be a target(s) of the
drug. Artemether appears to enhance the metabolism of glycogen
in adult schistosomes and the inhibition of lactate dehydroge-
nase thereby reducing the formation of lactate (Xiao et al., 1999).
The artemether-induced glycogen decrease in schistosomes was
shown to be associated with the inhibition of glycolysis rather
than an interference with glucose import (Xiao et al., 1997).
Schistosomes recovered from artemether treated animals retain
increased glycogen phosphorylase activity, but decreased glucose
uptake, due to their decreased glycogen content compared with
worms from untreated animals (Shuhua et al., 2000).
Another antimalarial drug mefloquine has shown promise as
an antischistosomal agent killing adult schistosomes as well as
schistosomula (Manneck et al., 2012). A single dose of meflo-
quine administered orally to mice infected with S. mansoni
or S. japonicum led to significant reductions in adults and
young developing worm burdens of both schistosome species
(Keiser et al., 2009). Mefloquine affinity chromatography of
crude extracts of S. mansoni schistosomula identified one spe-
cificmefloquine-binding protein which was the glycolytic enzyme
enolase (Manneck et al., 2012). This study also showed that
mefloquine and a specific enolase inhibitor—sodium fluoride
inhibited enolase activity in crude extracts of schistosomula,
although activity of a recombinant form of enolase was unaf-
fected (Manneck et al., 2012). Using isothermal microcalorime-
try, the functional inhibition of mefloquine and three known
glycolytic pathway inhibitors in schistosomes (sodium fluoride,
3-bromopyruvate, and menadione) were investigated in S. man-
soni in the presence or absence of glucose. The result suggested
a potential role for mefloquine as an inhibitor of glycolysis in
lifecycle stages where other targets such as haem degradation
are not pertinent (Manneck et al., 2012). Consideration could
be given to determine whether mefloquine treatment would be
of value in patients who have mixed malaria and Schistosoma
infections as such coinfections are not uncommon, particu-
larly in Africa, although a concern would be that this strategy
might select for Plasmodium parasites resistant to mefloquine.
Mefloquine monotherapy for schistosomiasis may prove superior
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to PZQ alone, since both juvenile and mature schistosome worms
would be targeted in an infection. Mefloquine, in combination
with PZQ, whether as a full or half dose regimen, can substan-
tially reduce the course of infection, thereby further confirming
its potential as an anti-schistosomal drug (Nashwa and Abdel-
Fattah, 2011). Both artemether and mefloquine have shown
promising anti-schistosomal features against adult and juve-
nileS. mansoni in both T cell-deficient mice and in relatively
infected age- and sex-matched immunologically intact control
mice (Keiser et al., 2010). Artemether treatment reduced total
worm burden ranging between 71.1 and 85.3%, while meflo-
quine induced reductions of total worm number between 80.4
and 97.8% in athymic and immunocompetent NMRImice. These
results suggest that artemether and mefloquine act T-cell inde-
pendently and that no synergy with the immune response occurs
(Keiser et al., 2010). Notably, mefloquine (Lariam) can pro-
duce severe neuropsychiatric and psychiatric side effects, which
can cause mental health issues (http://www.fda.gov/downloads/
Drugs/DrugSafety/ucm088616.pdf), which would be an impor-
tant consideration for its use in future as an anti-schistosome
therapy.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Glucose metabolism leading to ATP synthesis is critical for the
survival of schistosomes. Directly or indirectly interrupting or
blocking glucose uptake may represent a realistic strategy for drug
or vaccine development as it would likely lead to the starvation of
worms and an insufficient supply of energy for growth, pairing,
maturation, and fecundity.
However, this may not be a simple undertaking as many differ-
ent components participate in glucose uptake so the blocking or
inhibiting of one gene or gene product may stimulate the schis-
tosome worm to compensate by switching to a sub-pathway or
another related pathway, so as to allow the acquisition of glu-
cose. One logical approach may be to design multivalent vaccines
or drugs targeting two or more key genes that would depress
worm growth, reduce worm burden and fecal egg output, with the
simultaneous reduction in hepatic egg-associated disease pathol-
ogy. This strategy could first be developed and tested in the form
of a highly efficacious veterinary-based multivalent transmission
blocking vaccine (McManus and Loukas, 2008) for application in
animal reservoirs of S. japonicum in China and the Philippines,
and then extended to target the African schistosomes, S. mansoni,
and S. haematobium, with appropriately designed human clinical
trials.
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